Hemorrhagic Stroke in the SPARCL Study
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Goldstein et al1 reported a post hoc analysis of data from the Stroke Prevention with Aggressive Reductions in Cholesterol Levels (SPARCL) trial in order to determine the effects of high-dose atorvastatin in the secondary prevention of cerebrovascular events in men and women. However, they did not mention how statin therapy increased the risk of hemorrhagic stroke in men and women.
In fact, in the SPARCL trial as compared …